Grifols Sa (GRFS) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Grifols Sa  (NASDAQ: GRFS)

Grifols Sa's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Grifols Sa in the fourth quarter 2025?
Grifols Sa achieved a return on average equity (ROE) of 6.58 % in its fourth quarter 2025, this is above GRFS's average return on equity of 6.35%.
Grifols Sas equity during the 12 months ending in the fourth quarter 2025 are valued at $8 billion

ROE has advanced compared to 2.71% in the third quarter 2025, due to net income growth.

Within the Major Pharmaceutical Preparations industry 69 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 0 to 2096.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2024)
IV. Quarter
Y / Y Equity Change -11.67 % -11.67 % -11.67 % -11.67 % -
Y / Y Net Income Change 134.96 % - - - 17.79 %
Net Income (TTM) in Millions 560 238 238 238 238
Return On Equity (TTM) 6.58 % 2.71 % 2.63 % 2.55 % 2.47 %
GRFS's Total Ranking # 2096 # 0 # # #
Equity (TTM) in Millions 8,515 8,515 8,515 8,515 9,640
Seq. Equity Change 0 % 0 % 0 % -11.67 % 0 %
Seq. Net Income Change - - - - -

Back to GRFS Management Effectiveness >> GRFS's 5 Years Annual ROE >> Compare GRFS ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 70
Sector # 184
Overall # 2096

Return On Equity Statistics
High Average Low
12.66 %
6.35 %
2.27 %
(Dec 31 2018)   (Dec 31 2023)





GRFS Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 8,515 9,640 8,929 9,472 8,195
Y / Y Equity Change -11.67 % 7.96 % -5.74 % 15.59 % 8.88 %
Net Income in Millions 560 238 202 304 297
Y / Y Net Income Change 134.96 % 17.79 % -33.37 % 2.19 % -62.58 %
Return On Equity 6.58 % 2.47 % 2.27 % 3.21 % 3.63 %

Back to GRFS Management Effectiveness >> GRFS's 5 Years Annual ROE >> Compare GRFS ROE to its Competitors




Annual Roe Comment
In 2025 ROE improved to 6.58 % compared to the previous year, due to net income growth.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
GRFS's' Return on Equity at Yahoo Finance
GRFS's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for GRFS's Competitors
Subscribers only: Roe for Grifols Sa's Suppliers
Subscribers only: Return On Equity for GRFS's Customers




Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector ROE
Argenx Se  17.64 %
Kewaunee Scientific Corporation  17.52 %
Black Diamond Therapeutics Inc   17.46 %
Insulet Corporation  17.36 %
Ufp Technologies Inc   17.36 %
West Pharmaceutical Services Inc   16.68 %
Neurocrine Biosciences Inc   16.67 %
Ensign Group Inc  16.57 %
Ani Pharmaceuticals Inc  16.48 %
Genmab A  16.47 %
Strata Critical Medical Inc   16.46 %
Intuitive Surgical Inc   16.40 %
Cryoport inc   15.75 %
Lemaitre Vascular Inc   15.58 %
Option Care Health Inc   15.39 %
Sab Biotherapeutics Inc   15.17 %
Corcept Therapeutics Inc  15.11 %
Stryker Corp  15.04 %
Sotera Health Company  14.98 %
Regeneron Pharmaceuticals Inc   14.83 %
Quest Diagnostics Inc  14.56 %
Alkermes Plc   14.45 %
Keros Therapeutics Inc   14.25 %
Ardent Health Inc   14.09 %
Escalon Medical Corp   13.91 %
Ligand Pharmaceuticals Incorporated  13.86 %
Inmode Ltd   13.73 %
Cadre Holdings inc   13.50 %
Penumbra Inc  13.43 %
Seres Therapeutics Inc   13.30 %

Date modified: 2026-06-22T16:58:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.